<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EPIVIRÂ HBV- lamivudineÂ tablet, film coatedÂ </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use EPIVIR-HBV safely and effectively. See full prescribing information for EPIVIR-HBV.<br>EPIVIR-HBV (lamivudine) tablets for oral use<br>EPIVIR-HBV (lamivudine) oral solution<br>Initial U.S. Approval: 1995</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B UPON DISCONTINUATION OF EPIVIR-HBV, AND RISK OF HIV-1 RESISTANCE IF EPIVIR-HBV IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur. (5.1)</dd>
<dt>â€¢</dt>
<dd>Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy (including EPIVIR-HBV). Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (5.2)</dd>
<dt>â€¢</dt>
<dd>EPIVIRâ€‘HBV tablets and oral solution contain a lower dose of the same active ingredient (lamivudine) as EPIVIR tablets and oral Solution used to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. HIV-1 resistance may emerge in <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B patients with unrecognized or untreated HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> because the lamivudine dosage in EPIVIRâ€‘HBV is subtherapeutic and monotherapy is inappropriate for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. HIV counseling and testing should be offered to all patients before beginning treatment with EPIVIRâ€‘HBV and periodically during treatment. (5.3)</dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B UPON DISCONTINUATION OF EPIVIR-HBV, AND RISK OF HIV-1 RESISTANCE IF EPIVIR-HBV IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur. (5.1)</dd>
<dt>â€¢</dt>
<dd>Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy (including EPIVIR-HBV). Monitor hepatic function closely in these patients and, if appropriate, initiate anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B treatment. (5.2)</dd>
<dt>â€¢</dt>
<dd>EPIVIRâ€‘HBV tablets and oral solution contain a lower dose of the same active ingredient (lamivudine) as EPIVIR tablets and oral Solution used to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. HIV-1 resistance may emerge in <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B patients with unrecognized or untreated HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> because the lamivudine dosage in EPIVIRâ€‘HBV is subtherapeutic and monotherapy is inappropriate for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. HIV counseling and testing should be offered to all patients before beginning treatment with EPIVIRâ€‘HBV and periodically during treatment. (5.3)</dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>EPIVIR-HBV is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> associated with evidence of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B viral replication and active liver <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. (1)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Adult patients: 100Â mg, once daily. (2.2)</dd>
<dt>â€¢</dt>
<dd>Pediatric patients aged 2 to 17 years: 3 mg per kg once daily up to 100 mg once daily. Prescribe oral solution for pediatric patients requiring less than 100 mg daily. (2.3)</dd>
<dt>â€¢</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Doses of EPIVIR-HBV must be adjusted in accordance with renal function. (2.4)</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV should not be used with other medications that contain lamivudine or emtricitabine. (2.5)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Tablets: 100 mg (3)</dd>
<dt>â€¢</dt>
<dd>Oral Solution: 5 mg per mL (3)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to any of the components of the products. (4)  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>EPIVIR-HBV should not be used with other medications that contain lamivudine or with medications that contain emtricitabine. (5.4)</dd>
<dt>â€¢</dt>
<dd>Emergence of Resistance-Associated HBV Substitutions: Monitor ALT and HBV DNA levels during lamivudine treatment to aid in treatment decisions if emergence of viral mutants or loss of therapeutic response is suspected. (2.6, 5.5)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>The most common reported adverse reactions in those receiving EPIVIR-HBV (incidence greater than or equal to 10% and reported at a rate greater than placebo) were ear, nose and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (6.1)</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 at 1-877-844-8872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 3/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B UPON DISCONTINUATION OF EPIVIR-HBV<span class="Sup">Â®</span>, AND RISK OF HIV-1 RESISTANCE IF EPIVIR-HBV IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1.</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc"></a></h1>
<h2><a href="#section-2.1" class="toc">2.1 HIV Counseling and Testing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage in Adult Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage in Pediatric Patients</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosage Adjustment in Adult Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Important Administration Instructions</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Assessing Patients During Treatment</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc"></a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> With Steatosis</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> After Discontinuation of Treatment</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Risk of HIV-1 Resistance if EPIVIR-HBV Is Used in Patients With Unrecognized or Untreated HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Coadministration With Other Medications Containing Lamivudine or Emtricitabine</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Emergence of Resistance-Associated HBV Substitutions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients With <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired Liver Function</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Clinical Studies of EPIVIR-HBV in Adult Patients</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Clinical Studies of EPIVIR-HBV in Pediatric Subjects</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_41401c4f-7772-41aa-8895-109956f5df6f"></a><a name="section-1"></a><p></p>
<h1>WARNING: RISK OF <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B UPON DISCONTINUATION OF EPIVIR-HBV<span class="Sup">Â®</span>, AND RISK OF HIV-1 RESISTANCE IF EPIVIR-HBV IS USED IN PATIENTS WITH UNRECOGNIZED OR UNTREATED HIV-1.</h1>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span></span>: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including EPIVIR-HBV. Suspend treatment if clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity occur <span class="Italics">[see Warnings and Precautions (5.1)]</span>. </p>
<p><span class="Underline">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Upon Discontinuation of EPIVIR-HBV</span>: Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy (including EPIVIR-HBV). Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy. If appropriate, initiation of antiâ€‘<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</p>
<p><span class="Underline">Risk of HIV-1 Resistance if EPIVIR-HBV Is Used in Patients With Unrecognized or Untreated HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span>: EPIVIR-HBV is not approved for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> because the lamivudine dosage in EPIVIR-HBV is subtherapeutic and monotherapy is inappropriate for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. HIV-1 resistance may emerge in <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B-infected patients with unrecognized or untreated HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Counseling and testing should be offered to all patients before beginning treatment with EPIVIRâ€‘HBV and periodically during treatment <span class="Italics">[see Warnings and Precautions (5.3)].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_3e7e8232-ed9e-4da3-a5b9-05380ec2f8e6"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">EPIVIR-HBV is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> associated with evidence of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B viral replication and active liver <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> <span class="Italics">[see Clinical Studies (14.1, 14.2)].</span></p>
<p>The following points should be considered when initiating therapy with EPIVIR-HBV:</p>
<dl>
<dt>â€¢</dt>
<dd>Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV has not been evaluated in patients co-infected with HIV, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (HCV), or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> delta virus.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with decompensated liver disease.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ac16227e-30ce-43a3-81ef-cd8b12abef14"></a><a name="section-2.1"></a><p></p>
<h2>2.1 HIV Counseling and Testing</h2>
<p class="First">HIV counseling and testing should be offered to all patients before beginning treatment with EPIVIR-HBV and periodically during treatment because of the risk of emergence of resistant-HIV-1 and limitation of treatment options if EPIVIR-HBV is prescribed to treat <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in a patient who has unrecognized HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or acquires HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during treatment <span class="Italics">[see Warnings and Precautions (5.3)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a51334c5-ca2a-4a9b-b7a0-db393831f01a"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage in Adult Patients</h2>
<p class="First">The recommended oral dosage of EPIVIRâ€‘HBV is 100Â mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c1afaee-3f47-46da-ac48-e0504b0a9fb9"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosage in Pediatric Patients</h2>
<p class="First">The recommended oral dosage of EPIVIRâ€‘HBV for pediatric patients aged 2 to 17Â years is 3Â mg per kg once daily up to a maximum daily dosage of 100Â mg. The oral solution formulation should be prescribed for patients requiring a dosage less than 100Â mg or if unable to swallow tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2ab7662a-bfe1-434e-ad35-a7185ed4a79d"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosage Adjustment in Adult Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage recommendations for adult patients with reduced renal function are provided in Table 1 <span class="Italics">[see Clinical Pharmacology (12.3</span>)<span class="Italics">]</span>.</p>
<a name="_RefID0E6EAE"></a><table>
<caption><span>Table 1. Dosage of EPIVIR-HBV in Adult Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></caption>
<col width="33%">
<col width="41%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Creatinine Clearance (mL/min)</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Recommended Dosage of EPIVIR-HBV</span></p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">â‰¥50</p></td>
<td valign="top"><p class="First">100Â mg once daily</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">30-49</p></td>
<td valign="top"><p class="First">100Â mg first dose, then 50 mg once daily</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">15-29</p></td>
<td valign="top"><p class="First">100Â mg first dose, then 25Â mg once daily</p></td>
</tr>
<tr>
<td class="Rrule" valign="top"><p class="First">5-14</p></td>
<td valign="top"><p class="First">35Â mg first dose, then 15Â mg once daily</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"><p class="First">&lt;5</p></td>
<td class="Botrule" valign="top"><p class="First">35Â mg first dose, then 10Â mg once daily</p></td>
</tr>
</tbody>
</table>
<p>Following correction of the dosage for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, no additional dosage modification of EPIVIR-HBV is required after routine (4-hour) hemodialysis or peritoneal dialysis <span class="Italics">[see Clinical Pharmacology (12.3</span>)<span class="Italics">]</span>.</p>
<p>There are insufficient data to recommend a specific dosage of EPIVIR-HBV in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e5e11948-3544-4242-a3ab-85b43aa536f0"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Important Administration Instructions</h2>
<dl>
<dt>â€¢</dt>
<dd>EPIVIR-HBV tablets and oral solution may be administered with or without food.</dd>
<dt>â€¢</dt>
<dd>The tablets and oral solution may be used interchangeably <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</dd>
<dt>â€¢</dt>
<dd>The oral solution should be used for doses less than 100Â mg.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV should not be used with other medications that contain lamivudine or medications that contain emtricitabine <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f2118b0c-8ec9-4453-8830-3f9a82a6f05e"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Assessing Patients During Treatment</h2>
<p class="First">Patients should be monitored regularly during treatment by a physician experienced in the management of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B. During treatment, combinations of such events such as return of persistently elevated ALT, increasing levels of HBV DNA over time after an initial decline below assay limit, progression of clinical signs or symptoms of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, and/or worsening of hepatic necroinflammatory findings may be considered as potentially reflecting loss of therapeutic response. Such observations should be taken into consideration when determining the advisability of continuing therapy with EPIVIR-HBV.</p>
<p>The optimal duration of treatment, the durability of HBeAg seroconversions occurring during treatment, and the relationship between treatment response and longâ€‘term outcomes such as hepatocellular carcinoma or <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">decompensated cirrhosis</span> are not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_be28a8ed-d4f3-4c04-985a-ab0000a79f89"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>â€¢</dt>
<dd>EPIVIR-HBV tablets: 100Â mg, butterscotch-colored, film-coated, biconvex, capsule-shaped tablets imprinted with â€œGX CG5â€? on one side.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV oral solution: A clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, strawberry-bananaâ€“flavored liquid, containing 5Â mg of lamivudine per 1Â mL.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_1799c132-10d5-4b8c-be6d-223584a0e705"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">EPIVIR-HBV is contraindicated in patients who have experienced a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to lamivudine or to any component of the tablets or oral solution.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_99e84c99-c660-4880-b60a-97937e1a92d7"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> With Steatosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including EPIVIR-HBV and other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Most of these reports have described patients receiving nucleoside analogues for treatment of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, but there have been reports of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> in patients receiving lamivudine for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B. Particular caution should be exercised when administering EPIVIR-HBV to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with EPIVIR-HBV should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7474c55d-34ab-4a55-abe2-40be297cd748"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> After Discontinuation of Treatment</h2>
<p class="First">Clinical and laboratory evidence of exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have occurred after discontinuation of EPIVIR-HBV (these have been primarily detected by serum ALT elevations, in addition to the re-emergence of HBV DNA commonly observed after stopping treatment; see Table 4 for more information regarding frequency of posttreatment ALT elevations) <span class="Italics">[see Adverse Reactions (6.1)]</span>. Although most events appear to have been self-limited, fatalities have been reported in some cases. The causal relationship of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> exacerbation after discontinuation of EPIVIR-HBV has not been clearly established. Patients should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment with EPIVIR-HBV. There is insufficient evidence to determine whether re-initiation of EPIVIR-HBV alters the course of posttreatment exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8911f226-0bb3-4aa2-8fa6-330baab41946"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Risk of HIV-1 Resistance if EPIVIR-HBV Is Used in Patients With Unrecognized or Untreated HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
<p class="First">EPIVIR-HBV tablets and oral solution contain a lower lamivudine dose than the lamivudine dose in the following drugs used to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</p>
<dl>
<dt>â€¢</dt>
<dd>EPIVIR<span class="Sup">Â®</span> tablets and oral solution, </dd>
<dt>â€¢</dt>
<dd>COMBIVIR<span class="Sup">Â®</span> (lamivudine/zidovudine) tablets, </dd>
<dt>â€¢</dt>
<dd>EPZICOM<span class="Sup">Â®</span> (abacavir sulfate and lamivudine) tablets, and </dd>
<dt>â€¢</dt>
<dd>TRIZIVIR<span class="Sup">Â®</span> (abacavir, lamivudine, and zidovudine) tablets </dd>
</dl>
<p>The formulation and dosage of lamivudine in EPIVIR-HBV are not approved for patients co-infected with HBV and HIV. If a decision is made to administer lamivudine to such patients, the higher dosage indicated for HIV therapy should be used as part of an appropriate combination regimen, and the prescribing information for EPIVIR, COMBIVIR, EPZICOM, or TRIZIVIR as well as for EPIVIR-HBV should be consulted. HIV counseling and testing should be offered to all patients before beginning EPIVIR-HBV and periodically during treatment because of the risk of rapid emergence of resistant HIV and limitation of treatment options if EPIVIR-HBV is prescribed to treat <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B in a patient who has unrecognized or untreated HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or acquires HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e5c3e121-bc7b-470f-b106-8540f6ba6781"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Coadministration With Other Medications Containing Lamivudine or Emtricitabine</h2>
<p class="First">Do not coadminister EPIVIR-HBV with other lamivudine-containing products including EPIVIR (lamivudine), COMBIVIR (lamivudine/zidovudine), EPZICOM (abacavir/lamivudine), or TRIZIVIR (abacavir/lamivudine/zidovudine). </p>
<p>Do not coadminister EPIVIR-HBV with emtricitabine-containing products including ATRIPLA<span class="Sup">Â®</span> (efavirenz/emtricitabine/tenofovir disoproxil fumarate), COMPLERA<span class="Sup">Â®</span> (rilpivirine/emtricitabine/tenofovir disoproxil fumarate), EMTRIVA<span class="Sup">Â®</span> (emtricitabine), STRIBILD<span class="Sup">Â®</span> (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate), or TRUVADA<span class="Sup">Â®</span> (emtricitabine/tenofovir disoproxil fumarate).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fe2ea859-bcff-4b4b-a439-8e45f348b17c"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Emergence of Resistance-Associated HBV Substitutions</h2>
<p class="First">In controlled clinical trials, YMDD-mutant HBV was detected in subjects with on-EPIVIR-HBV re-appearance of HBV DNA after an initial decline below the solution-hybridization assay limit <span class="Italics">[see Microbiology (12.4)]</span>. Subjects treated with EPIVIR-HBV (adults and children) with YMDD-mutant HBV at 52 weeks showed diminished treatment responses in comparison with subjects treated with EPIVIR-HBV without evidence of YMDD substitutions, including the following: lower rates of HBeAg seroconversion and HBeAg loss (no greater than placebo recipients), more frequent return of positive HBV DNA, and more frequent ALT elevations. In the controlled trials, when subjects developed YMDD-mutant HBV, they had a rise in HBV DNA and ALT from their own previous on-treatment levels. Progression of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in some subjects with YMDD-mutant HBV, including subjects from the liver transplant setting and from other clinical trials. In clinical practice, monitoring of ALT and HBV DNA levels during treatment with EPIVIR-HBV may aid in treatment decisions if emergence of viral mutants is suspected.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d30969f4-4fe0-4778-9510-5f77bb540ba5"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis <span class="Italics">[see Warnings and Precautions (5.1)].</span>
</dd>
<dt>â€¢</dt>
<dd>Exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B after discontinuation of treatment <span class="Italics">[see Warnings and Precautions (5.2)].</span>
</dd>
<dt>â€¢</dt>
<dd>Risk of emergence of resistant HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see Warnings and Precautions (5.3)].</span>
</dd>
<dt>â€¢</dt>
<dd>Risk of emergence of resistant HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_069d1bb6-1a17-45cc-b7c7-994bc9eea75c"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Underline">Adverse Reactions in Clinical Trials of Adults With <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span> Clinical adverse reactions (regardless of investigatorâ€™s causality assessment) reported in greater or equal to 10% of subjects who received EPIVIR-HBV and reported at a rate greater than placebo are listed in Table 2.</p>
<a name="_RefID0EJNAE"></a><table>
<caption><span>Table 2. Clinical Adverse Reactions<span class="Sup">a</span> Reported in â‰¥10% of Subjects who Received EPIVIR-HBV for 52 to 68 Weeks and at an Incidence Greater than Placebo (Trials 1-3)</span></caption>
<col width="31%">
<col width="16%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">EPIVIR-HBV</span><br><span class="Bold">(nÂ =Â 332)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">(nÂ =Â 200)</span></p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Ear, Nose, and Throat</span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">Ear, nose, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">25%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">21%</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore throat</span></p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">13%</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Bold">Gastrointestinal</span></p></td>
<td class="Lrule Rrule" valign="top"></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14%</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Includes adverse events regardless of severity and causality assessment.</p>
<p>Specified laboratory abnormalities reported in subjects who received EPIVIR-HBV and reported at a rate greater than in subjects who received placebo are listed in Table 3.</p>
<a name="_RefID0E5VAE"></a><table>
<caption><span>Table 3. Frequencies of Specified Laboratory Abnormalities Reported During Treatment at a Greater Frequency in Subjects Treated with EPIVIR-HBV Than With Placebo (Trials 1â€‘3)<span class="Sup">a</span></span></caption>
<col width="28%">
<col width="36%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Test</span><br><span class="Bold">(Abnormal Level)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Subjects With Abnormality/Subjects With Observations</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">EPIVIR-HBV</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Serum Lipase â‰¥2.5 x ULN<span class="Sup">b</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">CPK â‰¥7 x baseline</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Platelets &lt;50,000/mm<span class="Sup">3</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Includes subjects treated for 52 to 68 weeks.</p>
<p><span class="Sup">b</span> Includes observations during and after treatment in the 2 placebo-controlled trials that collected this information.</p>
<p>ULN = Upper limit of normal.</p>
<p>In subjects followed for up to 16 weeks after discontinuation of treatment, posttreatment ALT elevations were observed more frequently in subjects who had received EPIVIR-HBV than in subjects who had received placebo. A comparison of ALT elevations between Weeks 52 and 68 in subjects who discontinued EPIVIR-HBV at Week 52 and subjects in the same trials who received placebo throughout the treatment course is shown in Table 4.</p>
<a name="_RefID0ENVAE"></a><table>
<caption><span>Table 4. Posttreatment ALT Elevations With No-Active-Treatment Follow-up (Trails 1 and 3)</span></caption>
<col width="71%">
<col width="20%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Abnormal Value</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Subjects With ALT Elevation/</span><br><span class="Bold">Subjects With Observations<span class="Sup">a</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">EPIVIR-HBV<span class="Sup">b</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo<span class="Sup">b</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">ALT â‰¥2 x baseline value</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">27%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">ALT â‰¥3 x baseline value<span class="Sup">c</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">21%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">ALT â‰¥2 x baseline value and absolute ALT &gt;500Â IU/L</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">7%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">ALT â‰¥2 x baseline value; and bilirubin &gt;2 x ULN and â‰¥2 x baseline value</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.9%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Each subject may be represented in one or more category.</p>
<p><span class="Sup">b</span> During treatment phase.</p>
<p><span class="Sup">c</span>Comparable to a Grade 3 toxicity in accordance with modified WHO criteria.</p>
<p>ULN = Upper limit of normal.</p>
<p>Adverse Reactions in Clinical Trials of Pediatric Subjects With <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><span class="Italics"><span class="Underline">:</span></span> Most commonly observed adverse reactions in the pediatric trials were similar to those in adult trials. Posttreatment transaminase elevations were observed in some subjects followed after cessation of EPIVIR-HBV.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c976288-0185-4b74-83da-8d35d7c697d2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the following adverse reactions have been reported during postmarketing use of EPIVIR-HBV. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to lamivudine.</p>
<p><span class="Italics"><span class="Underline">Blood and Lympatic System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>.</p>
<p><span class="Italics"><span class="Underline">Digestive</span></span>: <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>.</p>
<p><span class="Italics"><span class="Underline">Endocrine and Metabolic</span></span>: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>.</p>
<p><span class="Italics"><span class="Underline">General</span></span>: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>.</p>
<p><span class="Italics"><span class="Underline">Blood and Lymphatic</span></span>: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (including pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span> and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemias</span> progressing on therapy), <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>.</p>
<p><span class="Italics"><span class="Underline">Hepatic and Pancreatic</span></span>: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and steatosis, posttreatment exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> <span class="Italics">[see Boxed Warning]</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></span>: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Italics"><span class="Underline">Musculoskeletal</span></span>: <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Cramps</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
<p><span class="Italics"><span class="Underline">Nervous</span></span>: <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
<p><span class="Italics"><span class="Underline">Respiratory</span></span>: Abnormal breath sounds/<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>.</p>
<p><span class="Italics"><span class="Underline">Skin</span></span>: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_faa3ffb6-717e-40e1-9a13-dd3ad0fe8fee"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Lamivudine is predominantly eliminated in the urine by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim). No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_ed1a3565-daac-4d4b-b859-e55681caf9da"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_3081aa97-3c65-4f0f-bd0d-c2263a173cc3"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C.</span></p>
<p>There are no adequate and well-controlled trials of EPIVIR-HBV in pregnant women. Because animal reproduction studies are not always predictive of human response, EPIVIR-HBV should be used during pregnancy only if the potential benefits outweigh the potential risks to the fetus. </p>
<p><span class="Underline">Antiretroviral Pregnancy Registry:</span> To monitor maternal-fetal outcomes of pregnant women exposed to lamivudine, a Pregnancy Registry has been established. Healthcare providers are encouraged to register patients by calling 1-800-258-4263.</p>
<p><span class="Underline">Animal Data</span>: Animal reproduction studies in rats and rabbits revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Reproduction studies have been performed in rats and rabbits at orally administered doses up to 4,000Â mg/kg/day and 1,000Â mg/kg/day, respectively, producing plasma levels up to approximately 60Â times that for the adult HBV dose. Evidence of early embryolethality was seen in the rabbit at exposure levels similar to those observed in humans, but there was no indication of this effect in the rat at exposure levels up to 60Â times those in humans. </p>
<p>Studies in pregnant rats and rabbits showed that lamivudine is transferred to the fetus through the placenta.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_25c0b7f6-1d24-4cab-adb6-086273d457e5"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Lamivudine is excreted in human milk. Samples of breast milk obtained from 20 mothers receiving lamivudine monotherapy (300 mg twice daily, 6 times the recommended dosage for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) or combination therapy (150 mg lamivudine twice daily [3 times the recommended dosage for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>] and 300 mg zidovudine twice daily) had measurable concentrations of lamivudine. </p>
<p>Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue EPIVIR-HBV taking into consideration the importance of continued <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy to the mother and the known benefits of breastfeeding.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_7011a921-48a0-41b3-aa4b-d5855f1cdc3f"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">EPIVIR-HBV is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in pediatric patients aged 2 to 17 years <span class="Italics">[see Indications and Usage (1), Clinical Pharmacology (12.3), Clinical Studies (14.2)]</span>. The safety and efficacy of EPIVIR-HBV in pediatric patients younger than 2Â years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_d1cea85a-d614-4b0e-884c-5759a230d6c0"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of EPIVIR-HBV did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. In particular, because lamivudine is substantially excreted by the kidney and elderly patients are more likely to have decreased renal function, renal function should be monitored and dosage adjustments should be made accordingly <span class="Italics">[see Dosage and Administration (2.4), Clinical Pharmacology (12.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd451cb3-67df-4d8d-bf38-37951685b31c"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Reduction of the dosage of EPIVIR-HBV is recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> <span class="Italics">[see Dosage and Administration (2.4), Clinical Pharmacology (12.3)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4613633e-9038-4123-922f-14c2a179c5e4"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients With <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired Liver Function</span></h2>
<p class="First">No dose adjustment for lamivudine is required for patients with impaired hepatic function. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d24ce831-986b-46d8-939a-8a63a6067775"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no known antidote for EPIVIR-HBV. If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, the patient should be monitored, and standard supportive treatment utilized, as required.</p>
<p>Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> event.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d39f2854-64f6-4486-89ed-b6164279c2da"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">EPIVIR-HBV is a synthetic nucleoside analogue with activity against HBV. The chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2â€²,3â€²-dideoxy, 3â€²-thiacytidine. It has a molecular formula of C<span class="Sub">8</span>H<span class="Sub">11</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S and a molecular weight of 229.3. It has the following structural formula:</p>
<p><a name="id1427"></a><img alt="lamivudine structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83009c27-f54b-47df-b8b2-e2e4e0b8f4e8&amp;name=75d9a586-fb40-4b0a-84ad-4161e8d526f6-01.jpg"></p>
<p>Lamivudine is a white to off-white crystalline solid with a solubility of approximately 70Â mg per mL in water at 20Â°C.</p>
<p>EPIVIR-HBV tablets are for oral administration. Each tablet contains 100 mg of lamivudine and the inactive ingredients hypromellose, macrogol 400, magnesium stearate, microcrystalline cellulose, polysorbate 80, red iron oxide, sodium starch glycolate, titanium dioxide, and yellow iron oxide.</p>
<p>EPIVIR-HBV oral solution is for oral administration. One milliliter (1 mL) of EPIVIR-HBV oral solution contains 5Â mg of lamivudine (5 mg per mL) in an aqueous solution and the inactive ingredients artificial strawberry and banana flavors, citric acid (anhydrous), methylparaben, propylene glycol, propylparaben, sodium citrate (dihydrate), and sucrose (200Â mg).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_c36bdfb4-6cf1-42ef-b01d-3d294b08c5ea"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_d0e4bbf7-3c0b-49dd-8552-6de3f7402254"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Lamivudine is an antiviral agent <span class="Italics">[see Microbiology (12.4)].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_f4a028e7-0ed3-41f4-b57b-635c3483345d"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Pharmacokinetics in Adults:</span> The pharmacokinetic properties of lamivudine have been studied as single and multiple oral doses ranging from 5Â mg to 600Â mg per day administered to HBV-infected patients.</p>
<p><span class="Italics">Absorption and Bioavailability:</span> Following single oral doses of 100Â mg, the peak serum lamivudine concentration (C<span class="Sub">max</span>) in HBV-infected patients (steady state) and healthy subjects (single dose) was 1.28Â Â±Â 0.56Â mcg per mL and 1.05Â Â±Â 0.32Â mcg per mL (meanÂ Â±Â SD), respectively, which occurred between 0.5 and 2Â hours after administration. The area under the plasma concentration versus time curve (AUC<span class="Sub">[0-24Â h]</span>) following 100Â mg lamivudine oral single and repeated daily doses to steady state was 4.3Â Â±Â 1.4 (meanÂ Â±Â SD) and 4.7Â Â±Â 1.7Â mcgâ€¢hour per mL, respectively. The relative bioavailability of the tablet and oral solution were demonstrated in healthy subjects. Although the solution demonstrated a slightly higher peak serum concentration (C<span class="Sub">max</span>), there was no significant difference in systemic exposure (AUC) between the oral solution and the tablet. Therefore, the oral solution and the tablet may be used interchangeably.</p>
<p>After oral administration of lamivudine once daily to HBV-infected adults, the AUC and C<span class="Sub">max</span> increased in proportion to dose over the range from 5Â mg to 600Â mg once daily.</p>
<p>Absolute bioavailability in 12 adult subjects was 86%Â Â±Â 16% (meanÂ Â±Â SD) for the 150-mg tablet and 87%Â Â±Â 13% for the 10-mg per mL oral solution.</p>
<p><span class="Italics">Effects of Food on Oral Absorption:</span> The 100-mg tablet was administered orally to 24 healthy subjects on 2Â occasions, once in the fasted state and once with food (standard meal: 967Â kcal; 67Â grams fat, 33Â grams protein, 58Â grams carbohydrate). There was no significant difference in systemic exposure (AUC) in the fed and fasted states.</p>
<p><span class="Italics">Distribution:</span> The apparent volume of distribution after IV administration of lamivudine to 20Â asymptomatic HIV-1-infected subjects was 1.3Â Â±Â 0.4Â L per kg, suggesting that lamivudine distributes into extravascular spaces. Volume of distribution was independent of dose and did not correlate with body weight.</p>
<p>Binding of lamivudine to human plasma proteins is less than 36% and independent of dose. In vitro studies showed that over the concentration range of 0.1 to 100Â mcg per mL, the amount of lamivudine associated with erythrocytes ranged from 53% to 57% and was independent of concentration.</p>
<p><span class="Italics">Metabolism:</span> Metabolism of lamivudine is a minor route of elimination. In humans, the only known metabolite of lamivudine is the trans-sulfoxide metabolite. In 9Â healthy subjects receiving 300Â mg of lamivudine as single oral doses, a total of 4.2% (range 1.5% to 7.5%) of the dose was excreted as the trans-sulfoxide metabolite in the urine, the majority of which was excreted in the first 12Â hours. Serum concentrations of the trans-sulfoxide metabolite have not been determined.</p>
<p><span class="Italics">Elimination:</span> The majority of lamivudine is eliminated unchanged in urine by active organic cationic secretion. In 9Â healthy subjects given a single 300-mg oral dose of lamivudine, renal clearance was 199.7Â Â±Â 56.9Â mL per min (meanÂ Â±Â SD). In 20Â HIV-1-infected subjects given a single IV dose, renal clearance was 280.4Â Â±Â 75.2Â mL per min (meanÂ Â±Â SD), representing 71%Â Â±Â 16% (meanÂ Â±Â SD) of total clearance of lamivudine.</p>
<p>In most single-dose trials in HIV-1-infected subjects, HBV-infected subjects, or healthy subjects with serum sampling for 24Â hours after dosing, the observed mean elimination half-life (t<span class="Sub">Â½</span>) ranged from 5 to 7Â hours. In HIV-1-infected subjects, total clearance was 398.5Â Â±Â 69.1Â mL per min (meanÂ Â±Â SD). Oral clearance and elimination half-life were independent of dose and body weight over an oral dosing range of 0.25 to 10Â mg per kg.</p>
<p><span class="Underline">Special Populations:</span><span class="Italics"> Adults With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The pharmacokinetic properties of lamivudine have been determined in healthy subjects and in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, with and without hemodialysis (TableÂ 5).</p>
<a name="_Refid_80b28d70-ecfd-4693-8199-1a08a13a2"></a><table>
<caption><span>Table 5. Pharmacokinetic Parameters (Mean Â± SD) Dose-Normalized to a Single 100-mg Oral Dose of Lamivudine in Subjects With Varying Degrees of Renal Function</span></caption>
<col width="31%">
<col width="16%">
<col width="23%">
<col width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<p class="First"><span class="Bold">Creatinine Clearance Criterion</span></p>
<p><span class="Bold">(Number of Subjects)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">â‰¥80Â mL/min</span></p>
<p><span class="Bold">(nÂ =Â 9)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">20-59Â mL/min (nÂ =Â 8)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">&lt;20Â mL/min</span></p>
<p><span class="Bold">(nÂ =Â 6)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Creatinine clearance (mL/min)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">97</p>
<p>(range 82-117)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">39</p>
<p>(range 25-49)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">15</p>
<p>(range 13-19)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">max</span> (mcg/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.31Â Â±Â 0.35</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.85Â Â±Â 0.40</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.55Â Â±Â 0.31</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">AUC (mcgâ€¢h/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.28Â Â±Â 1.01</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14.67Â Â±Â 3.74</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">27.33Â Â±Â 6.56</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cl/F (mL/min)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">326.4Â Â±Â 63.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">120.1Â Â±Â 29.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">64.5Â Â±Â 18.3</p></td>
</tr>
</tbody>
</table>
<p>Exposure (AUC), C<span class="Sub">max</span>, and half-life increased with diminishing renal function (as expressed by creatinine clearance). Apparent total oral clearance (Cl/F) of lamivudine decreased as creatinine clearance decreased. T<span class="Sub">max</span> was not significantly affected by renal function. Based on these observations, it is recommended that the dosage of lamivudine be modified in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span><span class="Italics"> [see Dosage and Administration (2.4)]</span>.</p>
<p>Hemodialysis increases lamivudine clearance from a mean of 64 to 88Â mL per min; however, the length of time of hemodialysis (4Â hours) was insufficient to significantly alter mean lamivudine exposure after a single-dose administration. Continuous ambulatory peritoneal dialysis and automated peritoneal dialysis have negligible effects on lamivudine clearance. Therefore, it is recommended, following correction of dose for creatinine clearance, that no additional dose modification be made after routine hemodialysis or peritoneal dialysis.</p>
<p>It is not known whether lamivudine can be removed by continuous (24-hour) hemodialysis.</p>
<p><span class="Italics">Pediatric Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on lamivudine pharmacokinetics in pediatric patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B is not known.</p>
<p><span class="Italics">Adults With <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The pharmacokinetic properties of lamivudine in adults with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> are shown in Table 6. Subjects were stratified by severity of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<a name="_RefID0EVOAG"></a><table>
<caption><span>Table 6. Pharmacokinetic Parameters (MeanÂ Â±Â SD) Dose-Normalized to a Single 100-mg Dose of Lamivudine in Subjects With Normal or Impaired Hepatic Function</span></caption>
<col width="19%">
<col width="14%">
<col width="15%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<p class="First"><span class="Bold">Normal</span></p>
<p><span class="Bold">(nÂ =Â 8)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Impairment<span class="Sup">a</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Moderate</span></p>
<p><span class="Bold">(nÂ =Â 8)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Severe</span></p>
<p><span class="Bold">(nÂ =Â 8)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">max</span> (mcg/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.92Â Â±Â 0.31</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.06Â Â±Â 0.58</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.08Â Â±Â 0.27</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">AUC (mcgâ€¢h/mL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.96Â Â±Â 0.58</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.97Â Â±Â 1.36</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.30Â Â±Â 0.63</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">T<span class="Sub">max</span>(h)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.3Â Â±Â 0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.4Â Â±Â 0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.4Â Â±Â 1.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cl/F (mL/min)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">424.7Â Â±Â 61.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">456.9Â Â±Â 129.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">395.2Â Â±Â 51.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clr (mL/min)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">279.2Â Â±Â 79.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">323.5Â Â±Â 100.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">216.1Â Â±Â 58.0</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span> assessed by aminopyrine breath test.</p>
<p>Pharmacokinetic parameters were not altered by diminishing <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Therefore, no dose adjustment for lamivudine is required for patients with impaired hepatic function. Safety and efficacy of EPIVIR-HBV have not been established in the presence of decompensated liver disease <span class="Italics">[see Indications and Usage (1)]</span>.</p>
<p><span class="Italics">Adults Post-Hepatic Transplant:</span> Fourteen HBV-infected subjects received liver transplant following lamivudine therapy and completed pharmacokinetic assessments at enrollment, 2Â weeks after 100-mg once-daily dosing (pre-transplant), and 3Â months following transplant; there were no significant differences in pharmacokinetic parameters. The overall exposure of lamivudine is primarily affected by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; consequently, transplant patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> had generally higher exposure than patients with normal renal function. Safety and efficacy of EPIVIR-HBV have not been established in this population <span class="Italics">[see Indications and Usage (1)]</span>.</p>
<p><span class="Italics">Pediatric Subjects:</span> Lamivudine pharmacokinetics were evaluated in a 28-day dose-ranging trial in 53Â pediatric subjects with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B. Subjects aged 2 to 12Â years were randomized to receive lamivudine 0.35Â mg per kg twice daily, 3Â mg per kg once daily, 1.5Â mg per kg twice daily, or 4Â mg per kg twice daily. Subjects aged 13 to 17Â years received lamivudine 100Â mg once daily. Lamivudine T<span class="Sub">max</span> was 0.5 to 1Â hour. In general, both C<span class="Sub">max</span> and exposure (AUC) showed dose proportionality in the dosing range studied. Weight-corrected oral clearance was highest at age 2 and declined from 2 to 12Â years, where values were then similar to those seen in adults. A dose of 3Â mg per kg given once daily produced a steady-state lamivudine AUC (mean 5,953Â ngâ€¢hour per mLÂ Â±Â 1,562 SD) similar to that associated with a dose of 100Â mg per day in adults.</p>
<p><span class="Italics">Gender:</span> There are no significant gender differences in lamivudine pharmacokinetics.</p>
<p><span class="Italics">Race:</span> There are no significant racial differences in lamivudine pharmacokinetics.</p>
<p><span class="Underline">Drug Interactions: </span><span class="Italics">Interferon Alfa:</span> Multiple doses of lamivudine and a single dose of interferon were coadministered to 19 healthy male subjects in a pharmacokinetics study. Results indicated a 10% reduction in lamivudine AUC, but no change in interferon pharmacokinetic parameters when the 2 drugs were given in combination. All other pharmacokinetic parameters (C<span class="Sub">max</span>, T<span class="Sub">max</span>, and t<span class="Sub">Â½</span>) were unchanged. There was no significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between lamivudine and interferon alfa in this trial.</p>
<p><span class="Italics">Ribavirin:</span> InÂ vitro data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (nÂ =Â 18), stavudine (nÂ =Â 10), or zidovudine (nÂ =Â 6) were coadministered as part of a multi-drug regimen to HIVâ€‘1/HCV co-infected subjects.</p>
<p><span class="Italics">Trimethoprim/Sulfamethoxazole:</span> Lamivudine and trimethoprim/sulfamethoxazole (TMP/SMX) were coadministered to 14 HIV-positive subjects in a single-center, open-label, randomized, crossover trial. Each subject received treatment with a single 300-mg dose of lamivudine and TMP 160Â mg/SMX 800Â mg once a day for 5Â days with concomitant administration of lamivudine 300Â mg with the fifth dose in a crossover design. Coadministration of TMP/SMX with lamivudine resulted in an increase of 44%Â Â±Â 23% (meanÂ Â±Â SD) in lamivudine AUC, a decrease of 29%Â Â±Â 13% in lamivudine oral clearance, and a decrease of 30%Â Â±Â 36% in lamivudine renal clearance. The pharmacokinetic properties of TMP and SMX were not altered by coadministration with lamivudine.</p>
<p><span class="Italics">Zidovudine:</span> Lamivudine and zidovudine were coadministered to 12Â asymptomatic HIV-positive adult subjects in a single-center, open-label, randomized, crossover trial. No significant differences were observed in AUC or total clearance for lamivudine or zidovudine when the 2 drugs were administered together. Coadministration of lamivudine with zidovudine resulted in an increase of 39%Â Â±Â 62% (meanÂ Â±Â SD) in C<span class="Sub">max</span> of zidovudine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_37eacbc1-1084-4f27-9777-49fe0e162819"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Underline">Mechanism of Action:</span> Lamivudine is a synthetic nucleoside analogue. Intracellularly, lamivudine is phosphorylated to its active 5â€²-triphosphate metabolite, lamivudine triphosphate, 3TC-TP. The principal mode of action of 3TC-TP is the inhibition of the RNA- and DNA- dependent polymerase activities of HBV reverse transcriptase (rt) via DNA chain termination after incorporation of the nucleotide analogue into viral DNA. 3TC-TP is a weak inhibitor of mammalian Î±, Î², and Î³-DNA polymerases.</p>
<p><span class="Underline">Antiviral Activity:</span> Activity of lamivudine against HBV in cell culture was assessed in HBV DNA-transfected 2.2.15 cells, HB611 cells, and infected human primary hepatocytes. EC<span class="Sub">50</span> values (the concentration of drug needed to reduce the level of extracellular HBV DNA by 50%) varied from 0.01Â Î¼M (2.3Â ng per mL) to 5.6Â Î¼M (1.3Â mcg per mL) depending upon the duration of exposure of cells to lamivudine, the cell model system, and the protocol used. See the EPIVIR prescribing information for information regarding activity of lamivudine against HIV</p>
<p><span class="Underline">Resistance:</span> Lamivudine-resistant isolates were identified in subjects with virologic breakthrough, defined when using solution hybridization assay as the detection of HBV DNA in serum on 2 or more occasions after failing to detect HBV DNA on 2 or more occasions and defined when using PCR assay as a greater than 1Â log<span class="Sub">10</span> (10-fold) increase in serum HBV DNA from nadir during treatment in a subject who had an initial virologic response.</p>
<p>Lamivudine-resistant HBV isolates develop rtM204V/I substitutions in the YMDD motif of the catalytic domain of the viral reverse transcriptase. rtM204V/I substitutions are frequently accompanied by other substitutions (rtV173L, rtL180M) which enhance the level of lamivudine resistance or act as compensatory substitutions improving replication efficiency. Other substitutions detected in lamivudine-resistant HBV isolates include rtL80I and rtA181T.</p>
<p>In 4Â controlled clinical trials in adults with HBeAg-positive <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (CHB), YMDD-mutant HBV was detected in 81 of 335Â subjects receiving EPIVIR-HBV 100Â mg once daily for 52Â weeks. The prevalence of YMDD substitutions was less than 10% in each of these trials for subjects studied at 24Â weeks and increased to an average of 24% (range in 4Â trials: 16% to 32%) at 52Â weeks. In limited data from a long-term follow-up trial in subjects who continued 100Â mg per day EPIVIR-HBV after one of these trials, YMDD substitutions further increased from 18% (10 of 57) at 1 year to 41% (20 of 49), 53% (27 of 51), and 69% (31 of 45) after 2, 3, and 4Â years of treatment, respectively. Over the 5-year treatment period, the proportion of subjects who developed YMDD-mutant HBV at any time was 69% (40 of 58).</p>
<p>In a controlled trial, treatment-naive subjects with HBeAg-positive CHB were treated with EPIVIR-HBV or EPIVIR-HBV plus adefovir dipivoxil combination therapy. Following 104Â weeks of therapy, YMDD-mutant HBV was detected in 7 of 40 (18%) subjects receiving combination therapy compared with 15 of 35 (43%) subjects receiving therapy with only EPIVIR-HBV. In another controlled trial, combination therapy was evaluated in adult subjects with HBeAg-positive CHB who had YMDD-mutant HBV and diminished clinical and virologic response to EPIVIR-HBV. Following 52Â weeks of EPIVIR-HBV plus adefovir dipivoxil combination therapy (nÂ =Â 46) or therapy with only EPIVIR-HBV (nÂ =Â 49), YMDDâ€‘mutant HBV was detected less frequently in subjects receiving combination therapy, 62% versus 96.</p>
<p>A published trial suggested that the rates of lamivudine resistance in subjects treated for HBeAg-negative CHB appear to be more variable (0% to 27% at 1Â year and 10% to 56% at 2Â years).</p>
<p><span class="Italics">Pediatric Subjects</span>: In a controlled trial in pediatric subjects, YMDD-mutant HBV was detected in 31 of 166 (19%) subjects receiving EPIVIR-HBV for 52Â weeks. For a subgroup that remained on therapy with EPIVIR-HBV in a follow-up trial, YMDD substitutions increased from 24% (29 of 121) at 12Â months to 59% (68 of 115) at 24Â months and 64% (66 of 103) at 36Â months of treatment with EPIVIR-HBV.</p>
<p><span class="Underline">Cross-Resistance:</span> HBV containing lamivudine resistance-associated substitutions (rtL180M, rtM204I, rtM204V, rtL180MÂ andÂ rtM204V, rtV173LÂ andÂ rtL180MÂ andÂ rtM204V) retain susceptibility to adefovir dipivoxil but have reduced susceptibility to entecavir (30 fold) and telbivudine (greater than 100Â fold). The lamivudine resistance-associated substitution rtA181T results in diminished response to adefovir and telbivudine. Similarly, HBV with entecavir resistance-associated substitutions (I169T/M250V and T184G/S202I) have greater than 1,000-fold reductions in susceptibility to lamivudine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_8350ca73-c459-4618-9277-8e51a0cbcb83"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_2a138ace-40a6-42a4-a2ee-f7631dff8912"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis:</span> Long-term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 34Â times (mice) and 200Â times (rats) those observed in humans at the recommended therapeutic dose for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B. </p>
<p><span class="Underline">Mutagenesis:</span> Lamivudine was not active in a microbial mutagenicity screen or an in vitro cell transformation assay, but showed weak in vitro mutagenic activity in a cytogenetic assay using cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay. However, lamivudine showed no evidence of in vivo genotoxic activity in the rat at oral doses of up to 2,000Â mg per kg producing plasma levels of 60 to 70Â times those in humans at the recommended dose for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B.</p>
<p><span class="Underline">Impairment of Fertility:</span> In a study of reproductive performance, lamivudine administered to rats at doses up to 4,000Â mg per kg per day, producing plasma levels 80 to 120 times those in humans, revealed no evidence of impaired fertility and no effect on the survival, growth, and development to weaning of the offspring.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_f760957e-7a49-4fdc-89e0-6e4b8a62ddee"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f41c9f78-9f28-4d73-a061-1b9c17a1c373"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Clinical Studies of EPIVIR-HBV in Adult Patients</h2>
<p class="First">The safety and efficacy of EPIVIR-HBV 100Â mg once daily versus placebo were evaluated in 3Â controlled trials in subjects with compensated <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. All subjects were aged 16Â years or older and had <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (serum HBsAg-positive for at least 6Â months) accompanied by evidence of HBV replication (serum HBeAg-positive and positive for serum HBV DNA) and persistently elevated ALT levels and/or chronic <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> on liver biopsy compatible with a diagnosis of chronic <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span>. The results of these trials are summarized below.</p>
<dl>
<dt>â€¢</dt>
<dd>Trial 1 was a randomized, double-blind trial of EPIVIR-HBV 100Â mg once daily versus placebo for 52Â weeks followed by a 16-week no-treatment period in 141 treatment-naive US subjects.</dd>
<dt>â€¢</dt>
<dd>Trial 2 was a randomized, double-blind, 3-arm trial that compared EPIVIR-HBV 25Â mg once daily versus EPIVIR-HBV 100Â mg once daily versus placebo for 52Â weeks in 358 Asian subjects.</dd>
<dt>â€¢</dt>
<dd>Trial 3 was a randomized, partially-blind trial conducted primarily in North America and Europe in 238 subjects who had ongoing evidence of active <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B despite previous treatment with interferon alfa. The trial compared EPIVIR-HBV 100Â mg once daily for 52Â weeks, followed by either EPIVIR-HBV 100Â mg or matching placebo once daily for 16Â weeks (Arm 1), versus placebo once daily for 68Â weeks (Arm 2).</dd>
</dl>
<p>Principal endpoint comparisons for the histologic and serologic outcomes in subjects receiving EPIVIR- HBV (100Â mg daily) or placebo in these trials are shown in the following tables.</p>
<a name="_Refid_82a8b4cc-e1ae-4ae3-9aad-cd24c1c6a"></a><table>
<caption><span>Table 7. Histologic Response at Week 52 Among Adult Subjects Receiving EPIVIR-HBV 100Â mg Once Daily or Placebo</span></caption>
<col width="18%">
<col width="16%">
<col width="10%">
<col width="16%">
<col width="10%">
<col width="16%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Assessment</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 3</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">EPIVIR</span>-<span class="Bold">HBV</span></p>
<p><span class="Bold">(nÂ =Â 62)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(nÂ =Â 63)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">EPIVIR</span>-<span class="Bold">HBV</span></p>
<p><span class="Bold">(nÂ =Â 131)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(nÂ =Â 68)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">EPIVIR</span>-<span class="Bold">HBV</span></p>
<p><span class="Bold">(nÂ =Â 110)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(nÂ =Â 54)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Improvement<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">55%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">25%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">56%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">26%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">56%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">26%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">No Improvement</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">27%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">59%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">36%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">62%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">25%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">54%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Missing Data</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">18%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">20%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Improvement was defined as a greater than or equal to 2-point decrease in the Knodell Histologic Activity Index (HAI) at WeekÂ 52 compared with pretreatment HAI. Subjects with missing data at baseline were excluded.</p>
<a name="_RefID0E65AG"></a><table>
<caption><span>Table 8. HBeAg Seroconverters<span class="Sup">a</span> at Week 52 Among Adult Subjects Receiving EPIVIR-HBV 100Â mg Once Daily or Placebo</span></caption>
<col width="17%">
<col width="16%">
<col width="10%">
<col width="16%">
<col width="10%">
<col width="16%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Seroconversion</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 2</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 3</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">EPIVIR</span>-<span class="Bold">HBV</span></p>
<p><span class="Bold">(nÂ =Â 63)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(nÂ =Â 69)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">EPIVIR</span>-<span class="Bold">HBV</span></p>
<p><span class="Bold">(nÂ =Â 140)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(nÂ =Â 70)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">EPIVIR</span>-<span class="Bold">HBV</span></p>
<p><span class="Bold">(nÂ =Â 108)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(nÂ =Â 53)</span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Seroconverters</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">17%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">16%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">15%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13%</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> Three-component seroconversion was defined as WeekÂ 52 values showing loss of HBeAg, gain of HBeAb, and reduction of HBV DNA to below the solution-hybridization assay limit. Subjects with negative baseline HBeAg or HBV DNA assay were excluded from the analysis.</p>
<p>Normalization of serum ALT levels was more frequent with EPIVIR-HBV treatment compared with placebo in Trials 1-3.</p>
<p>The majority of subjects treated with EPIVIR-HBV showed a decrease of HBV DNA to below the assay limit early in the course of therapy. However, reappearance of assay-detectable HBVÂ DNA during treatment with EPIVIR-HBV was observed in approximately one-third of subjects after this initial response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aaeacae4-250c-4caa-aa12-92d75a7cf2d5"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Clinical Studies of EPIVIR-HBV in Pediatric Subjects</h2>
<p class="First">The safety and efficacy of EPIVIR-HBV were evaluated in a double-blind clinical trial in 286Â subjects aged from 2 to 17Â years, who were randomized (2:1) to receive 52Â weeks of EPIVIR-HBV (3Â mg per kg once daily to a maximum of 100Â mg once daily) or placebo. All subjects had compensated <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B accompanied by evidence of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus replication (positive serum HBeAg and positive for serum HBV DNA by a research branched-chain DNA assay) and persistently elevated serum ALT levels. The combination of loss of HBeAg and reduction of HBV DNA to below the assay limit of the research assay, evaluated at Week 52, was observed in 23% of subjects treated with EPIVIR-HBV and 13% of placebo-treated subjects. Normalization of serum ALT was achieved and maintained to Week 52 more frequently in subjects treated with EPIVIR-HBV compared with placebo (55% versus 13%). As in the adult controlled trials, most subjects treated with EPIVIR-HBV had decreases in HBV DNA below the assay limit early in treatment, but about one third of subjects with this initial response had reappearance of assay-detectable HBV DNA during treatment. Adolescents (aged 13 to 17Â years) showed less evidence of treatment effect than younger pediatric subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_3b3512d3-2c00-4dd6-abc9-087a50377a03"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">EPIVIR-HBV tablets, 100Â mg, are butterscotch-colored, film-coated, biconvex, capsule-shaped tablets imprinted with â€œGX CG5â€? on one side.</p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0893-1</td>
<td align="center">100 MG</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">butterscotch-colored</td>
<td align="center">0173-0662</td>
</tr></tbody>
</table>
<p><span class="Bold">Store at 25Â°C (77Â°F), excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature].</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ffdb3300-8c61-4038-86c6-69435d9ae550"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">Advise the patient to read the FDA-approved patient labeling (Patient Information).</span></p>
<p><span class="Underline">Advice for the Patient</span></p>
<dl>
<dt>â€¢</dt>
<dd>Advise patients to remain under the care of a physician while taking EPIVIR-HBV and discuss any new symptoms or concurrent medications with their physician.</dd>
<dt>â€¢</dt>
<dd>Advise patients that EPIVIR-HBV is not a cure for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, that the long-term treatment benefits of EPIVIR-HBV are unknown at this time, and, in particular, that the relationship of initial treatment response to outcomes such as hepatocellular carcinoma and <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">decompensated cirrhosis</span> is unknown <span class="Italics">[see Dosage and Administration (2.6)]</span>. </dd>
<dt>â€¢</dt>
<dd>Inform patients that deterioration of liver disease has occurred in some cases when treatment was discontinued. Instruct patients to discuss any changes in regimen with their physician <span class="Italics">[see Warnings and Precautions (5.2)]</span>.</dd>
<dt>â€¢</dt>
<dd>Inform patients that emergence of resistant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus and worsening of disease can occur during treatment, and they should promptly report any new symptoms to their physician <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</dd>
<dt>â€¢</dt>
<dd>Counsel patients on the importance of testing for HIV to avoid inappropriate therapy and development of resistant HIV. HIV counseling and testing should be offered before starting EPIVIR-HBV and periodically during therapy. </dd>
<dt>â€¢</dt>
<dd>Advise patients that EPIVIR-HBV tablets and EPIVIR-HBV oral solution contain a lower dose of the same active ingredient (lamivudine) as EPIVIR tablets, EPIVIR oral solution, COMBIVIR tablets, EPZICOM tablets, and TRIZIVIR tablets. EPIVIR-HBV should not be taken concurrently with EPIVIR, COMBIVIR, EPZICOM, or TRIZIVIR <span class="Italics">[see Dosage and Administration (2.1), Warnings and Precautions (5.3, 5.4)]</span>. </dd>
<dt>â€¢</dt>
<dd>Advise patients not to take EPIVIR-HBV with emtricitabine-containing medicines, such as ATRIPLA, COMPLERA, EMTRIVA, STRIBILD, or TRUVADA <span class="Italics">[see Warnings and Precautions (5.4)].</span>
</dd>
<dt>â€¢</dt>
<dd>Advise patients that treatment with EPIVIR-HBV has not been shown to reduce the risk of transmission of HBV to others through sexual contact or blood contamination <span class="Italics">[see Use in Specific Populations (8.1)]</span>.<dl>
<dt>âˆ˜</dt>
<dd><span class="Bold">Do not share needles or other injection equipment.</span></dd>
<dt>âˆ˜</dt>
<dd><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></dd>
<dt>âˆ˜</dt>
<dd>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>Advise diabetic patients that each 20-mL dose of EPIVIR-HBV oral solution contains 4Â grams of sucrose <span class="Italics">[see Description (11)]</span>.</dd>
</dl>
<p>EPIVIR-HBV is a registered trademark of the GlaxoSmithKline group of companies.</p>
<p>EPIVIR, COMBIVIR, EPZICOM, and TRIZIVIR are registered trademarks of the ViiV Healthcare group of companies.</p>
<p>The other brands listed are trademarks of their respective owners and are not trademarks of the GlaxoSmithKline group of companies. The makers of these brands are not affiliated with and do not endorse the GlaxoSmithKline group of companies or its products.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Manufactured under agreement from</p>
<p><span class="Bold">Shire Pharmaceuticals Group plc</span></p>
<p>Basingstoke, UK</p>
<p>Â©2013, GlaxoSmithKline group of companies. All rights reserved.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_e00bd4a2-8dbc-4c0b-ac80-8803c2ded1f8"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First">Patient Information</p>
<p><span class="Bold">EPIVIR HBV<span class="Sup">Â®</span></span> (EP-i-veer h-b-v)</p>
<p><span class="Bold">(lamivudine)</span></p>
<p><span class="Bold">tablets</span></p>
<p><span class="Bold">EPIVIR HBV<span class="Sup">Â®</span></span> (EP-i-veer h-b-v)</p>
<p><span class="Bold">(lamivudine)</span></p>
<p><span class="Bold">oral solution</span></p>
<p>Read this Patient Information before you start taking EPIVIR-HBV and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about EPIVIR-HBV?</span></p>
<p><span class="Bold">EPIVIR-HBV can cause serious side effects, including: </span></p>
<p><span class="Bold">Build-up of an acid in your blood (<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>).</span><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can happen in some people who take EPIVIR-HBV or similar (nucleoside analogs) medicines. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a serious medical emergency that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can be hard to identify early because the symptoms could seem like symptoms of other health problems. <span class="Bold">Call your healthcare provider right away if you get any of the following symptoms that could be signs of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>:</span></p>
<dl>
<dt>â€¢</dt>
<dd>feel very weak or tired</dd>
<dt>â€¢</dt>
<dd>unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></dd>
<dt>â€¢</dt>
<dd>trouble breathing</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd>feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs</dd>
<dt>â€¢</dt>
<dd>feel dizzy or light-headed</dd>
<dt>â€¢</dt>
<dd>have a fast or irregular heartbeat</dd>
</dl>
<p><span class="Bold">Severe liver problems.</span>Severe liver problems can happen in people who take EPIVIR-HBV or similar medicines. In some cases these liver problems can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your liver may become large (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and you may develop fat in your liver (steatosis) when you take EPIVIR-HBV. <span class="Bold">Call your healthcare provider right away if you get any of the following signs of liver problems</span>:</p>
<dl>
<dt>â€¢</dt>
<dd>your skin or the white part of your eyes turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</dd>
<dt>â€¢</dt>
<dd>dark â€œtea-coloredâ€? urine</dd>
<dt>â€¢</dt>
<dd>light-colored bowel movements (stools)</dd>
<dt>â€¢</dt>
<dd>loss of appetite for several days or longer</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></dd>
</dl>
<p><span class="Bold">You may be more likely to get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or severe liver problems if you are female, very overweight, or have been taking nucleoside analogue medicines for a long time.</span></p>
<p><span class="Bold">Worsening liver disease.</span>Your <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may become worse after stopping treatment with EPIVIR-HBV. Worsening liver disease can be serious and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. If you stop treatment with EPIVIR-HBV, your healthcare provider will need to check your health and do blood tests to check your liver for at least several months after you stop taking EPIVIR-HBV.</p>
<p><span class="Bold">Risk of HIV-1 resistance in people with unknown HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or in people with untreated HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span>If you have or get HIV that is not being treated with medicines while taking EPIVIR-HBV, the HIV virus may develop resistance to certain HIV medicines and become harder to treat<span class="Bold">.</span></p>
<dl>
<dt>â€¢</dt>
<dd>Your healthcare provider should offer you counseling and testing for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> before you start treatment for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B with EPIVIR-HBV and during treatment.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV tablets and EPIVIRâ€‘HBV oral solution contain a lower dose of lamivudine than other medicines that contain lamivudine and are used to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. See <span class="Bold">â€œWhat should I tell my healthcare provider?â€? </span>for a list of medicines you should not take with EPIVIR-HBV.</dd>
</dl>
<p><span class="Bold">Resistant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus (HBV).</span>The <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus can change (mutate) during your treatment with EPIVIR-HBV and become harder to treat (resistant). If this happens, your liver disease can become worse and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Tell your healthcare provider right away if you have any new symptoms.</p>
<p><span class="Bold">What is EPIVIR-HBV?</span></p>
<p>EPIVIR-HBV is a prescription medicine used to treat long-term (chronic) <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) when the disease is progressing and there is liver <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>).</p>
<dl>
<dt>â€¢</dt>
<dd>EPIVIR-HBV will not cure HBV.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV may lower the amount of HBV in your body.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV may lower the ability of HBV to multiply and infect new liver cells.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV may improve the condition of your liver.</dd>
<dt>â€¢</dt>
<dd>The long-term benefits of taking EPIVIR-HBV for treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> are not known.</dd>
</dl>
<p>It is not known if EPIVIR-HBV is safe and effective in:</p>
<dl>
<dt>â€¢</dt>
<dd>people with chronic HBV who have a severely damaged liver that is unable to work properly (decompensated liver disease)</dd>
<dt>â€¢</dt>
<dd>people with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> D (delta) virus</dd>
<dt>â€¢</dt>
<dd>people who have had a liver transplant</dd>
<dt>â€¢</dt>
<dd>children with chronic HBV less than 2 years of age</dd>
</dl>
<p><span class="Bold">EPIVIR-HBV does not stop you from spreading HBV to others by sex, sharing needles, or being exposed to your blood. Avoid doing things that can spread HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</span></p>
<dl>
<dt>â€¢</dt>
<dd>Do not share or re-use needles or other injection equipment.</dd>
<dt>â€¢</dt>
<dd>Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</dd>
<dt>â€¢</dt>
<dd>Do not have any kind of sex without protection. Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</dd>
</dl>
<p>A vaccine is available to protect people at risk for becoming infected with HBV. You can ask your healthcare provider for information about this vaccine.</p>
<p><span class="Bold">Who should not take EPIVIR-HBV?</span></p>
<p>Do not take EPIVIR-HBV if you are allergic to lamivudine or any of the ingredients in EPIVIR-HBV. See the end of this leaflet for a complete list of ingredients in EPIVIR-HBV.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking EPIVIR-HBV?</span></p>
<p><span class="Bold">Before you take EPIVIR-HBV, tell your healthcare provider if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</dd>
<dt>â€¢</dt>
<dd>have kidney problems</dd>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Each 20-mL dose (100 mg) of EPIVIR-HBV oral solution contains 4 grams of sucrose.</dd>
<dt>â€¢</dt>
<dd>have any other medical condition </dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. It is not known if EPIVIR-HBV will harm your unborn baby. </dd>
<dt>Â </dt>
<dd>
<span class="Bold">Pregnancy Registry.</span> There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry. </dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. EPIVIR-HBV can pass into your breast milk and may harm your baby. You and your healthcare provider should decide if you will take EPIVIR-HBV or breastfeed.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins,and herbal supplements.</p>
<p><span class="Bold">Do not take EPIVIR-HBV if you also take:</span></p>
<dl>
<dt>â€¢</dt>
<dd>other medicines that contain lamivudine (COMBIVIR<span class="Sup">Â®</span>, EPIVIR<span class="Sup">Â®</span>, EPZICOM<span class="Sup">Â®</span>, TRIZIVIR<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>medicines that contain emtricitabine (ATRIPLA<span class="Sup">Â®</span>, COMPLERA<span class="Sup">Â®</span>, EMTRIVA<span class="Sup">Â®</span>, STRIBILD<span class="Sup">Â®</span>, TRUVADA<span class="Sup">Â®</span>)</dd>
</dl>
<p><span class="Bold">How should I take EPIVIR-HBV?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take EPIVIR-HBV exactly as your healthcare provider tells you to take it.</dd>
<dt>â€¢</dt>
<dd>Do not change your dose or stop taking EPIVIR-HBV without talking with your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>EPIVIR-HBV is taken 1 time each day.</dd>
<dt>â€¢</dt>
<dd>Your healthcare provider may prescribe a lower dose if you have problems with your kidneys.</dd>
<dt>â€¢</dt>
<dd>For children 2 to 17 years of age, your healthcare provider will prescribe the right dose of EPIVIR-HBV based on your childâ€™s body weight.</dd>
<dt>â€¢</dt>
<dd>Take EPIVIR-HBV by mouth, with or without food.</dd>
<dt>â€¢</dt>
<dd>Tell your healthcare provider if you have trouble swallowing tablets. EPIVIR-HBV also comes as a liquid (oral solution).</dd>
<dt>â€¢</dt>
<dd>If you take too much EPIVIR-HBV, call your healthcare provider or go to the nearest hospital emergency room right away.</dd>
<dt>â€¢</dt>
<dd>It is important to stay under your healthcare providerâ€™s care while taking EPIVIR-HBV. Tell your healthcare provider about any new symptoms that you have.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of EPIVIR-HBV?</span></p>
<p><span class="Bold">EPIVIR-HBV may cause serious side effects, including: </span></p>
<p>See "<span class="Bold">What is the most important information I should know about EPIVIR-HBV?</span>".</p>
<p><span class="Bold">The most common side effects of EPIVIR-HBV include:</span></p>
<dl>
<dt>â€¢</dt>
<dd>ear, nose, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of EPIVIR-HBV. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store EPIVIR-HBV?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store EPIVIRâ€‘HBV tablets and oral solution at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</dd>
<dt>â€¢</dt>
<dd>Keep bottles of EPIVIR-HBV oral solution tightly closed.</dd>
</dl>
<p><span class="Bold">Keep EPIVIR-HBV and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of EPIVIR-HBV</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use EPIVIR-HBV for a condition for which it was not prescribed. Do not give EPIVIR-HBV to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about EPIVIR-HBV that is written for health professionals.</p>
<p>For more information, go to www.gsk.com or call 1-800-25-5249.</p>
<p><span class="Bold">What are the ingredients in EPIVIR-HBV?</span></p>
<p><span class="Bold">Active ingredient:</span> lamivudine.</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<p><span class="Bold">EPIVIR-HBVtablets:</span> hypromellose, macrogol 400, magnesium stearate, microcrystalline cellulose, polysorbate 80, red iron oxide, sodium starch glycolate, titanium dioxide, and yellow iron oxide.</p>
<p><span class="Bold">EPIVIR-HBV</span> o<span class="Bold">ral solution: </span>artificial strawberry and banana flavors, citric acid (anhydrous), methylparaben, propylene glycol, propylparaben, sodium citrate (dihydrate), and sucrose (200 mg per mL).</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>EPIVIR-HBV is a registered trademark of the GlaxoSmithKline group of companies.</p>
<p>EPIVIR, COMBIVIR, EPZICOM, and TRIZIVIR are registered trademarks of the ViiV Healthcare group of companies.</p>
<p>The other brands listed are trademarks of their respective owners and are not trademarks of the GlaxoSmithKline group of companies. The makers of these brands are not affiliated with and do not endorse the GlaxoSmithKline group of companies or its products.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Manufactured under agreement from</p>
<p><span class="Bold">Shire Pharmaceuticals Group plc</span></p>
<p>Basingstoke, UK</p>
<p>Â©2013, GlaxoSmithKline group of companies. All rights reserved.</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
USA<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f7a0fd82-7619-4f8f-a372-cdceeef64d39"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL</h1>
<p class="First">Label Image for <span class="Bold">53808-0893<br>100mg</span></p>
<div class="Figure"><img alt="Label Image for 100mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83009c27-f54b-47df-b8b2-e2e4e0b8f4e8&amp;name=100mg%20shire%20pharms.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EPIVIRÂ 		
					HBV</strong><br><span class="contentTableReg">lamivudine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0893(NDC:0173-0662)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LAMIVUDINE</strong> (LAMIVUDINE) </td>
<td class="formItem">LAMIVUDINE</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (butterscotch-colored) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GX;CG5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0893-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021003</td>
<td class="formItem">01/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack(53808-0893)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>50cf8e19-72f4-4202-895f-cc9f81c2ca6f</div>
<div>Set id: 83009c27-f54b-47df-b8b2-e2e4e0b8f4e8</div>
<div>Version: 1</div>
<div>Effective Time: 20140303</div>
</div>
</div>Â <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
